We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA批准Imfinzi（durvalumab）+ BCG用于高危非肌层浸润性膀胱癌。复发风险降低32%。了解肿瘤泌尿学的突破。
